ReviewFrontiers in cardiovascular medicine2026
Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically evaluate the efficacy of beta-blockers (BBs) in preventing left ventricular dysfunction (LVD) induced by anthracyclines and trastuzumab. It combines traditional meta-analysis with Bayesian network meta-analysis ( Methods: We conducted a systematic literature search in databases such as PubMed, Web of Science, EMBASE, and the Cochrane Library to identify eligible randomized controlled trials (RCTs). Traditional meta-analysis and Bayesian NMA were used to evaluate the impact of BBs on left ventricular ejection fraction (LVEF) and cancer therapy-related cardiotoxicity events (CTRCE). The cumulative ranking probabilities (SUCRA) were used to rank the efficacy of different BBs. Data analysis was performed using STATA 16.0 and R 4.5.0 software. Results: A total of 19 RCTs were included for LVEF outcomes and 15 for CTRCE outcomes. For LVEF, BBs were superior to controls overall (WMD = 2.19, 95% CI 1.40-2.98; Conclusion: BBs demonstrated robust protective effects in maintaining LVEF and reducing CTRCE risk, with bisoprolol showing the greatest efficacy, followed by carvedilol. The evidence supports prioritizing BBs during chemotherapy with individualized selection based on treatment regimen and patient profile. However, large-scale, multicenter RCTs with long-term follow-up are warranted to confirm long-term benefits and to explore combination strategies with other cardioprotective agents. Systematic Review Registration: identifier CRD420251233424.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.